Transcriptional repression of the human p53 gene by cobalt chloride mimicking hypoxia  by Lee, Seok Geun et al.
Transcriptional repression of the human p53 gene by
cobalt chloride mimicking hypoxia
Seok Geun Lee, Hyeon Lee, Hyune Mo Rho*
School of Biological Sciences, Seoul National University, Seoul 151-742, South Korea
Received 13 September 2001; accepted 20 September 2001
First published online 10 October 2001
Edited by Julio Celis
Abstract The switch to an angiogenic phenotype is known to be
a fundamental determinant of neoplastic growth and tumor
progression. We herein report that the transcription of the human
p53 gene was repressed by treatment with a hypoxia-mimicking
concentration of cobalt chloride and alone by hypoxia-inducible
factor 1K. Analyses of serial deletions, site-directed mutageneses
and heterologous promoter systems showed that the site
responsible for the repression by both factors was the E-box
element in the promoter of the p53 gene. These results alongside
previous data suggest that the loss of p53 including the
transcriptional repression may play an important role in the
angiogenic switch during tumorigenesis. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Regions of vascular de¢ciency or defective microcirculation
in growing tumors are deprived of O2, glucose, and other
nutrients. Apoptosis induced by nutrient de¢ciency counter-
balances cell proliferation and limits tumor growth [1,2].
Clonal evolution of tumor cells in this hypoxic microenviron-
ment results from selection of subpopulations that not only
resist apoptosis, but also promote the formation of new blood
vessels [3,4]. In addition to promoting further growth of the
primary tumor, cellular adaptation to hypoxia and tumor
neovascularization are strongly correlated with the risk of
invasion and metastasis [4^6]. The switch to an angiogenic
phenotype is considered to be a fundamental determinant of
neoplastic progression [1,7].
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric tran-
scription factor that regulates O2 homeostasis and physiologic
responses to O2 deprivation [8,9]. HIF-1 consists of two sub-
units, HIF-1K and HIF-1L that belong to a subfamily of basic
helix^loop^helix transcription factors containing a PAS (Per-
ARNT-Sim) motif [10]. A decrease in cellular O2 tension leads
to elevation of HIF-1 activity via stabilization of the HIF-1K
protein; conversely, ubiquitin-mediated proteolysis of HIF-1K
on exposure to a normoxic environment results in rapid decay
of HIF-1 activity [10^12]. HIF-1 is a key transcriptional me-
diator of metabolic adaptation and VEGF-mediated angio-
genesis in response to hypoxia [8,9,13^17]. Although these
responses serve to maintain O2 homeostasis in normal tissues,
they are also experienced by tumors to facilitate neovascular-
ization and growth. Akin to their role in vascular develop-
ment and remodeling in normal tissues, HIF-1K and VEGF
facilitate tumor angiogenesis, and both HIF-1K and VEGF
are overexpressed in a wide variety of human cancers
[4,14,16,18^22].
The human p53 tumor suppressor gene encodes a multi-
functional transcription factor that mediates cellular responses
to diverse stimuli, including DNA damage and hypoxia [23].
In addition to being an integral component of the surveillance
mechanisms that arrest cell cycle progression under adverse
conditions, p53 is also involved in mediating hypoxia-induced
apoptosis and inducing inhibitors of angiogenesis such as
thrombospondin-1 (TSP-1) [1,24,25]. Evidence also suggests
that p53 negatively regulates VEGF expression [26^28]. So-
matic mutations of the p53 gene represent one of the most
common genetic alterations in human cancers, and the acqui-
sition of such defects is strongly associated with tumor pro-
gression and metastasis [29]. The p53 is known to promote
Mdm2-mediated ubiquitination and proteasomal degradation
of the HIF-1K, and the loss of p53 in tumor cells has also been
known to enhance HIF-1K levels and augment HIF-1-depen-
dent transcriptional activation in response to hypoxia [30].
Here, we investigated whether hypoxia-mimicking cobalt chlo-
ride (CoCl2) [31] and HIF-1K would regulate the transcription
of the p53 gene.
2. Materials and methods
2.1. Plasmids
p53p1CAT reporter plasmid was kindly provided by David Reis-
man [32], and p53-Luc vector was purchased from Stratagene. The
other reporter plasmids (p53-416, p53-220, p53-67, p53mCPE,
p53mUB, p53mEbox, p53mE2F, p53Eboxtk, and p53mEboxtk) were
constructed as described previously [33]. HIF-1K expression vector
was presented as a gift by Dr. T.K. Kim (Harvard University).
2.2. Transient transfection assay
All transient transfections and CAT assays were performed as de-
scribed previously [33]. The conversion of chloramphenicol to its ace-
tylated form was quanti¢ed by using the BAS radio-analytic imaging
system according to the manufacturer’s instructions (Fuji). Luciferase
assay was conducted as described previously [34]. Normalization of
transfection e⁄ciency was conducted using the Bradford assay (Bio-
Rad). All experiments were repeated at least three times, and a rep-
resentative autoradiograph is shown. Standard deviations were 6 12%
in all cases.
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2.3. RT-PCR
Total RNA was extracted from HeLa cells using the acid guanidi-
nium thiocyanate^phenol^chloroform method [35]. RT-PCR was con-
ducted as described previously [34]. The cyclophilin gene was used as
an internal control. Oligonucleotide sequences are as follows: p53
upper (5P-ATGGAGGAGCCGCAGTCAGATCCTA-3P), p53 lower
(5P-CGCGTCGACTCAGTCTGAGTCAGGCCCTTCTGTC-3P), cy-
clophilin upper (5P-AGCACTGGAGAGAAAGGATT-3P) and cyclo-
philin lower (5P-AACCACTCAGTCTTGGCAGT-3P)
3. Results
In order to study the e¡ect of CoCl2, mimicking hypoxia,
on the promoter activity of the human p53 gene, the p53
promoter-CAT construct (p53p1CAT) was transfected into
HeLa cells. As shown in Fig. 1A, the CAT activity of the
p53 promoter was gradually repressed by up to about 3.5-
fold as a result of increasing the concentration of CoCl2.
These results imply that CoCl2 represses the activity of the
p53 promoter. As the HIF-1K subunit is known to play major
roles in response to hypoxia [8,15,17,36], we also observed
that CoCl2 induced the HIF-1K protein in HeLa cells as pre-
viously reported (data not shown) [10,37]. Therefore, we also
investigated whether HIF-1K would regulate the activity of
the p53 promoter. To study the e¡ect of HIF-1K on the pro-
moter activity of the human p53 gene, p53p1CAT reporter
plasmid was cotransfected with HIF-1K expression vector.
The CAT activity of the p53 promoter was gradually re-
pressed by up to about 4.5-fold through increasing the HIF-
1K expression vector (Fig. 1B). These results imply that the
expression of the p53 gene was repressed by hypoxia-mimick-
ing CoCl2 and HIF-1K.
In order to identify the target sequence of CoCl2-mediated
repression in the upstream region of the p53 gene, deletion
mutants of the p53 promoter were prepared and transfected
into HeLa cells. CoCl2-mediated repression was observed in
Fig. 1. The e¡ect of CoCl2 and HIF-1K on the promoter of the hu-
man p53 gene. A: The p53-CAT reporter plasmid (p53p1CAT) was
transfected into HeLa cells, and the transfected cells were treated
with CoCl2 for 16 h as indicated. The relative CAT activity is
shown compared to that obtained for the untreated cells. B: Tran-
scriptional activity of the p53 promoter was measured by cotransfec-
tion with the HIF-1K expression vector as indicated. The basal
CAT activity of p53p1CAT is designated as 1.0 and each CAT ac-
tivity is shown as a value relative to this basal activity.
Fig. 2. Identi¢cation of the repression site by CoCl2 in the p53 pro-
moter. A: Serial deletion mutant reporter plasmids of the p53 pro-
moter were transfected into HeLa cells, and the transfected cells
were treated with CoCl2 (100 WM) for 16 h as indicated. CAT activ-
ities without (3) or with (+) CoCl2 are indicated by the blank bars
and solid bars, respectively. The basal CAT activity of p53-416 is
designated as 1.0 and each CAT activity is shown as a value relative
to this basal activity. CoCl2-mediated repression is observed in each
construct to be about four-fold. Error bars indicate standard errors.
B: The schematic representation of the transcriptional binding sites
and approximate location in the p53 promoter. EBS, ETS binding
site; C/EBP, CCAAT/enhancer binding protein site; CPEp53, p53
core promoter element; arrow, major transcription start site. C:
Transient transfection assays were performed using each of the mu-
tant p53 promoter-CAT reporter plasmids, and the transfected cells
were treated with CoCl2 (100 WM) for 16 h as indicated. The basal
CAT activity of p53-67 is designated as 1.0 and each CAT activity
is shown as a value relative to this basal activity.
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each construct by three- to ¢ve-fold regardless of the pro-
moter strength (Fig. 2A). These results suggested that the
target sequence of CoCl2-mediated repression is located in
the region of nt 367 to +18, in which there are four tran-
scriptional factor binding sites (CPEp53, NF-UB, E-box ele-
ment and E2F) (Fig. 2B). As shown in Fig. 2A (lanes 1, 3, and
5), the basal CAT activity of each deletion reporter plasmid
resulted in a similar pattern as in a previous report [33]. To
determine which site is speci¢cally involved in CoCl2-medi-
ated repression of the p53 promoter activity, we constructed
four plasmids bearing mutations on each p53 core promoter
element (CPEp53), NF-UB binding site, E-box element and
E2F binding site (Fig. 2C). When each mutant transfected
into the HeLa cells, CoCl2-mediated repression was main-
tained in the p53mCPE, p53mUB mutants and p53mE2F,
but not in the plasmid p53mEbox (Fig. 2C). These results
indicate that the transcriptional repression of the p53 gene
by CoCl2 is mediated through the E-box element. The basal
promoter activity of p53mCPE was lower than that of the
other plasmids (Fig. 2C, lane 3) as previously reported [38].
The e¡ect of CoCl2 and HIF-1K was tested on the E-box
elements attached to the thymidine kinase (tk) promoter of
herpes simplex virus. The CoCl2 and HIF-1K did not change
the activity of the tk promoter (Fig. 3A, lanes 1^3). The
CoCl2 and HIF-1K repressed the CAT activity of pEboxtk,
which suggests the repression by CoCl2 and HIF-1K through
the E-box element (Fig. 3A, lanes 4^6). In contrast, CoCl2
and HIF-1K did not repress the pmEboxtk (Fig. 3A, lanes
7^9). These results showed that the transcriptional repression
of the p53 promoter by CoCl2 and HIF-1K was also mediated
through the E-box element.
The promoter of the human p53 tumor suppressor gene is
also transactivated by the c-Myc/Max heterodimer, which
binds to the E-box element [32]. We therefore investigated
whether CoCl2 a¡ects the transactivation of the human p53
gene by c-Myc. The c-Myc expression vector was cotrans-
fected with the plasmid containing the E-box element. The
c-Myc activated the p53 promoter about three-fold, presum-
ably through the heterodimerization with endogenous Max
protein (Fig. 3B, lane 2). However, when treated with 100
WM CoCl2, the c-Myc did not activate p53 promoter activity
(Fig. 3B, lane 4). Rather, it was more strongly repressed in the
Fig. 3. A: The e¡ect of CoCl2 and HIF-1K on the synthetic E-box
and mutated E-box in the heterologous promoter. The plasmid
pBLCAT2 has a tk promoter (tkp). The plasmid pEboxtk and pmE-
boxtk have three copies of the E-box and mutated E-box element,
respectively, in front of tkp in the pBLCAT2. Each heterologous re-
porter plasmid was transfected with HIF-1K expression vector, or
the transfected cell with each reporter plasmid was treated with 100
WM CoCl2 for 16 h. B: The inhibitory e¡ect of CoCl2 on the tran-
scriptional activation of the p53 promoter by c-Myc. Each plasmid
of p53-67 and p53mEbox was transfected with c-Myc expression
vector into HeLa cells, and the transfected cells were treated with
100 WM CoCl2 for 16 h, as indicated. Error bars indicate standard
errors.
Fig. 4. Repression of the expression of the p53 gene in response to
CoCl2. A: The endogenous p53 mRNA is gradually repressed by in-
creasing the concentration of CoCl2 in HeLa cells. The p53 mRNA
was rarely detected in the treatment of 100 WM. B: The p53-Luc
vector contains the luciferase reporter gene (Luc) driven by a basic
promoter element (TATA box) joined to multiple repeats (15U) of
p53 binding element (p53RE). Luciferase activity was determined in
HeLa cell lysates 16 h after treatment of CoCl2. Error bars indicate
standard errors.
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presence of c-Myc (about four-fold) than in its absence (about
three-fold). The activity of the p53mEbox was neither acti-
vated by c-Myc, nor repressed by CoCl2 in the presence of
c-Myc (Fig. 3B, lanes 5^8). These results suggest that CoCl2
also represses the transcriptional activation of the p53 pro-
moter by the c-Myc, which binds to the E-box element.
In order to determine whether the endogenous p53 gene is
repressed by treatment of CoCl2, the p53 mRNA level was
measured by RT-PCR in HeLa cells. As shown in Fig. 4A, the
expression of the p53 gene was repressed by the treatment of
CoCl2 in a dose-dependent manner. In particular, the p53
mRNA evidently disappeared at a concentration of 100 WM
(Fig. 4A, lane 3). We also investigated whether CoCl2 a¡ects
the transactivating function of p53 protein. When p53-Luc
vector was transfected into HeLa cells to determine if CoCl2
a¡ects p53 function as a transcription factor, CoCl2 repressed
luciferase activity from p53-Luc reporter vector (Fig. 4B).
These results indicated that the endogenous p53 gene was re-
pressed by CoCl2, which is known to be a hypoxia-mimicking
agent, and that functionally, at least as a transcription factor,
p53 was also inactivated by CoCl2.
4. Discussion
Recognition of the importance of angiogenesis for the
growth and metastasis of cancers has raised fundamental
questions regarding the molecular mechanisms of the angio-
genic switch during tumor progression. The genetic alterations
involved in tumorigenesis are also responsible for the pheno-
typic characteristics of cancer cells. The p53 tumor suppressor
gene is one of the most frequently mutated genes in human
cancers [29]. In addition to p53 mutations, which occur in
V50% of all cancers (involving s 50 tissue types), p53 is
also inactivated by viral oncoproteins such as the E6 protein
of cervical cancer-associated human papillavirus 16 and 18,
adenovirus E1A, X protein of hepatitis B virus, core protein
of hepatitis C virus, and SV40 large T antigen [29,33]. These
observations indicated that the loss of p53 function, via so-
matic mutations, transcriptional inactivation or expression of
viral oncoproteins, contributes to activation of the angiogenic
switch during tumorigenesis.
p53 has been known to inhibit HIF-stimulated transcription
and promote Mdm2-mediated ubiquitination and proteasomal
degradation of the HIF-1K [30,39]. Loss of p53 in tumor cells
enhances HIF-1K levels and augments HIF-1-dependent tran-
scriptional activation of VEFG gene in response to hypoxia,
and forced expression of HIF-1K in p53-expressing tumor
cells increases hypoxia-induced VEGF expression and aug-
ments neovascularization and growth of tumor xenografts
[30]. Expression of HIF-1K protein, HIF-1 DNA binding ac-
tivity, and VEGF mRNA are increased in p53 3/3 knockout
colon carcinoma cells as compared with the parental p53 +/+
cells, and in renal clear cell carcinoma cell lines, the loss of
von Hippel^Lindau tumor suppressor function results in con-
stitutive high-level expression of HIF-1K [22,40]. Thus, in ad-
dition to hypoxia, both oncogene activation and tumor sup-
pressor gene inactivation seem to be associated with increased
HIF-1K expression.
Here we demonstrated that CoCl2 and HIF-1K repressed
the transcription of the human p53 gene through the E-box
element and that the p53 protein was functionally, at least as
a transcription factor, inactivated by CoCl2. HIF-1K is also
known to interact with the p53 protein, which inhibits the
functions of HIF-1K [22,30,39]. The angiogenic switch is regu-
lated by changes in the relative balance between inducers,
such as VEGF, and inhibitors, such as TSP-1, of endothelial
cell proliferation and migration [3]. The p53-mediated inhibi-
tion of VEFG expression, together with the ability of p53 to
upregulate TSP-1, indicated that p53 provides dual functions
that regulate angiogenesis [24,30]. Thus, the loss of p53 func-
tions, such as somatic mutation, inactivation by viral onco-
proteins, and especially transcriptional repression, during tu-
morigenesis deregulates both arms of the balance, providing a
potent stimulus for neovascularization and tumor progression.
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